FDAnews
www.fdanews.com/articles/61627-oscient-pharmaceuticals-corporation-and-abbott-canada-enter-into-commercialization-agreement-for-factive-tablets

OSCIENT PHARMACEUTICALS CORPORATION AND ABBOTT CANADA ENTER INTO COMMERCIALIZATION AGREEMENT FOR FACTIVE TABLETS

August 10, 2006

Oscient Pharmaceuticals Corporation has granted the commercialization rights to FACTIVE (gemifloxacin mesylate) tablets in Canada to Abbott Canada, the Canadian affiliate of Abbott. In exchange for those rights, Abbott Canada has agreed to a transfer price on product purchases and to make certain payments to Oscient upon achievement of certain regulatory and sales milestones. Specific financial terms were not disclosed.
BioSpace